FRX Related Analyst Ratings
-
BMO Capital Starts Forest Laboratories (FRX) at Underperform
-
Forest Laboratories (FRX) 'Day of Reckoning' Not Far Off
-
Janney Montgomery Scott Starts Forest Laboratories (FRX) at Buy
-
Goldman Sachs Upgrades Forest Laboratories (FRX) to Neutral
-
Cantor Fitzgerald's Conviction Calls For 2013
-
Cowen Upgrades Forest Laboratories (FRX) to Outperform
-
Citi Starts Forest Laboratories (FRX) at Buy
-
Mizuho Securities Starts Forest Laboratories (FRX) at Buy
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Christmas Comes Early
-
Jefferies Maintains a 'Buy' on Forest Laboratories (FRX); Quickly Moving Into Pole Position
-
Cantor Fitzgerald Reiterates a 'Sell' on Ironwood Pharmaceuticals (IRWD); Shares Still Overvalued
-
JPMorgan Downgrades Forest Laboratories (FRX) to Neutral
-
UBS Maintains a 'Neutral' on Forest Laboratories (FRX); An Aclidinium Approval As Expected
-
Needham & Company Maintians a 'Hold' on Forest Laboratories (FRX); Q1 Review; Reviewing FDA Calendar
-
Baird Maintains a 'Neutral' on Forest Laboratories (FRX); Q1 a Net-Neutral Event
-
Barclays Adjusts Estimates on Forest Laboratories (FRX); Q1 Preview: Icahn Not Issue Til August
-
Barclays Previews Forest Laboratories (FRX) Analyst Day Meeting: Shares Becoming Popular Destination to 'Hide'
-
Leerink Swann Upgrades Forest Laboratories (FRX) to Outperform; U.S. Portfolio Warrants a Premium
-
Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX
-
Cantor Fitzgerald Maintains a 'Buy' on Warner Chilcott (WCRX); Let's Make It Official
-
UPDATE - Auriga Initiates Coverage on Forest Laboratories (FRX); Lack of Near Term Catalysts Keep Us Sidelined
-
Auriga Starts Forest Laboratories (FRX) at Hold
-
Cantor Fitzgerald Maintains a 'Buy' on Forest Laboratories (FRX); Raising PT and Estimates
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Continued Growth Challenges, But There Is A Success Factor
-
UPDATE - UBS Initiates Coverage on Ironwood Pharma (IRWD) with a Neutral; Sidelined Heading Into PDUFA
-
Needham & Company Maintains a 'Hold' on Forest Labs (FRX); FDA Overwhelmingly Backs Approval of Aclidinium
-
Cantor Fitzgerald Raises Price Target on Forest Laboratories (FRX) on Q3 Upside and New FY12 Guidance
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Strength of Established Products Drives EPS Beat as New Launches Begin Gaining Traction
-
Cantor Fitzgerald Starts Forest Laboratories (FRX) at Buy; Can Forest Find Its Roots?
-
Argus Downgrades Forest Laboratories (FRX) to Hold
-
Jefferies Maintains a 'Buy' on Forest Laboratories (FRX); Remains Our Top Pick in the Sector
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Modest Launch Performance, Increased OpEx Combine to Reveal Softness & Rare EPS Miss
-
ThinkEquity Starts Forest Laboratories (FRX) at Buy
-
Goldman Sachs Downgrades Forest Laboratories (FRX) to Sell
-
UBS Maintains a 'Neutral' on Forest Laboratories (FRX); Updated Thoughts
-
Citadel Securities Starts Forest Laboratories (FRX) at Neutral; Forest Beginning to Clear
-
Jefferies Lifts Price Target on and Estiamtes On Forest Laboratories (FRX)
-
Argus Upgrades Forest Laboratories (FRX) to Buy
-
Collins Stewart Raises Price Target on Forest Laboratories (FRX) Following Carl Icahn's 13D Filing
-
Caris & Co. Downgrades Forest Laboratories (FRX) to Above Average
-
JPMorgan Upgrades Forest Laboratories (FRX) to Overweight
-
Jefferies Bullish on Cubist's (CBST) CXA-201; Raises PT to $44
-
Jefferies Raises Estimates and Price Target On Forest Laboratories (FRX)
-
Barclays Maintains an 'Equalweight' on Forest Laboratories (FRX); Long-Term Outlook Clearer; Thesis Unchanged
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Solid Q4 Earnings Take Back Seat as Floor Set for Post-Cliff 2013 EPS Performance
-
Credit Suisse Upgrades Forest Laboratories (FRX) to Outperform
-
Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Clinical Data Deal Brings Solid SSRI Entrant Viibryd Though “Too Little Too Late” & Undifferentiated Profile Concerns
-
Wedbush Downgrades Clinical Data (CLDA) to Neutral; Forest Buying CLDA for $30 Plus CVR,
-
Merriman Curhan Ford Downgrades Forest Laboratories (FRX) to Neutral
-
Citi Downgrades Forest Laboratories (FRX) to Hold
Back to FRX Stock Lookup
